VANCOUVER, BRITISH COLUMBIA -- (Marketwire) -- 05/08/12 -- biOasis Technologies Inc. (TSX VENTURE:BTI) today announces test results from its Transcend therapeutic development program directed towards the delivery of targeted therapeutic compounds to the brain. The results demonstrate that Transcend can increase considerably the delivery of an anti-amyloid beta antibody (anti-AB) to the brain. Further to the work performed at the National Research Council of Canada (NRC) and announced by the company on November 1st, 2011, the brains of the subject animals were sent to the iCapture Centre (St Paul's Hospital, Vancouver, BC) for quantitative analysis by confocal microscopy. The analysis showed that Transcend successfully delivered greater than 4 fold more anti-AB into the brain when compared to anti-AB on its own. One of the challenges facing companies currently testing anti-AB antibodies in clinical trials for the treatment of Alzheimer's disease (AD) is getting enough of the antibody to cross the blood-brain barrier and into the brain. The passive immunization of AD patients using antibodies directed at the AB peptide is a potential therapeutic strategy aimed at reducing amyloid plaques in the brain. The plaques, consisting of insoluble amyloid B protein are thought to be responsible for the neuronal cell death and the associated cognitive impairment seen in AD patients. Approaches that can efficiently deliver these antibodies into the brain may be the key for their use in the treatment of AD.
"As we reported earlier, a number of pharmaceutical companies are in early and late stage clinical trials studying anti-AB antibodies as potential treatments for AD. biOasis has shown over the past several months that its Transcend Vector can deliver antibodies such as anti-AB (reported here), Herceptin®(1), and other large and small molecules across the blood-brain barrier to achieve higher concentrations than those seen with the effector molecules on their own." said Rob Hutchison, CEO. "Through the use of confocal microscopic imaging, we have been able to quantify the increase in brain penetration using Transcend.